Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Chronic HCV infection must be documented by positive anti-HCV antibody using a third-generation enzyme immunoassay and persistent detection of HCV RNA in the blood for at least 6 months.~* Participants must be infected with HCV genotype 1 (line probe assay; INNO-LiPA HCV II, Innogenetics) and maybe treatment-naïve or treatment-experienced (treatment experienced specifically means prior treatment with interferon, standard or pegylated, with or without ribavirin with therapy stopped \> 6 months prior to screening).~* Eligible participants must have had alanine aminotransferase and aspartate aminotransferase \< 5 x upper limit of normal (ULN), plasma HCV RNA \> 5 log10 international units (IU)/milliliter (mL), and have had no clinical or laboratory evidence of hepatic decompensation for inclusion (must have platelets \> 100,000/cubic millimeter \[mm\^3\], total bilirubin \< 1.5 x ULN, prothrombin time \< 1.5 x ULN, or albumin \> 3.0 grams/deciliter \[g/dL\] for inclusion).~* Women were eligible if not pregnant or breast-feeding.~* Women of childbearing potential (that is, not surgically sterile or confirmed post menopausal) must have had confirmed negative pregnancy tests. All participants must practice a medically acceptable form of contraception.~Exclusion Criteria:~* Human immunodeficiency virus or hepatitis B virus co-infection known cirrhosis.~* Prior history of clinical hepatic decompensation (ascites, jaundice, encephalopathy, or variceal hemorrhage), alcoholic or other forms of chronic liver disease, evidence of hepatocellular carcinoma (α-fetoprotein \> 50 nanograms/mL), creatinine clearance \< 80 mL/minute (using Cockcroft-Gault equation), hemoglobin \< 10 g/dL, neutrophils \< 1500/mm\^3, and abnormal thyroid function tests (thyroid stimulating hormone \> 2.5 microIU/mL, free T4 \> ULN), or, a positive test result for illicit drugs, alcohol, or drug abuse within the past 12 months.~* Participants who have had significant gastrointestinal, thyroid, renal, cardiovascular, pulmonary, oncologic, or neurological disease, or who are currently receiving immunomodulators (corticosteroids), investigational, nephrotoxic or hepatotoxic drugs (for example, phenytoin, carbamazepine, isonicotinic acid hydrazide, azole anti-fungal agents such as ketoconazole, and aminoglycoside antibiotics), non-steroidal anti-inflammatory agents, ibuprofen or acetaminophen (on a daily basis) will also be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).